Established in late 2017, Velabs Therapeutics GmbH is EMBL’s most recent spin-off project. The company uses a proprietary high-throughput screening platform based on a broad portfolio of novel EMBL microfluidics technology. Velabs offers screening services for therapeutic antibodies from natural sources and against difficult targets. Visit www.velabs-therapeutics.com for further information.